{
    "Clinical Trial ID": "NCT01045421",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Phase 1: MLN8237 10 mg",
        "  MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles for a maximum of 24 months, or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study.",
        "INTERVENTION 2: ",
        "  Phase 1: MLN8237 20 mg",
        "  MLN8237 (alisertib) 20 mg, enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles for a maximum of 24 months, or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Each patient must meet all of the following inclusion criteria to be enrolled in the study:",
        "  18 years or older",
        "  Histologically or cytologically confirmed metastatic and/or advanced solid tumor (Phase 1 only)",
        "  Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); Squamous cell cancer of the head and neck (HNSCC); or Gastroesophageal adenocarcinoma",
        "  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
        "  Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse",
        "  Male patients who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse",
        "  Voluntary written consent",
        "  Wiling to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures",
        "  Measurable disease (Phase 2 only)",
        "Exclusion Criteria:",
        "  Patients meeting any of the following exclusion criteria are not to be enrolled in the study:",
        "  Female patients who are pregnant or lactating",
        "  Serious medical or psychiatric illness that could interfere with protocol completion",
        "  Receipt of more than 2 previous cytotoxic chemotherapeutic regimens (4 previous regimens for breast cancer). There is no limit on the number of prior noncytotoxic therapies",
        "  Prior treatment with Aurora A-targeted agents, including MLN8237",
        "  Prior treatment with high-dose chemotherapy",
        "  Prior allogeneic bone marrow or other organ transplant",
        "  Antineoplastic therapy, radiation therapy or any experimental therapy 21 days prior to first dose of MLN8237",
        "  Symptomatic brain metastasis",
        "  Radiotherapy to greater than 25% of bone marrow",
        "  Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected",
        "  Myocardial infarction within 6 months of enrollment",
        "  Uncontrolled cardiovascular condition",
        "  Major surgery within 14 days of first dose of MLN8237",
        "  Active infection requiring systemic therapy, or other serious infection",
        "  Inability to swallow oral medication",
        "  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C",
        "  Patients requiring full systemic anticoagulation",
        "  History of uncontrolled sleep apnea syndrome",
        "  Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)",
        "  Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of the following considered related to alisertib by investigator: Grade 4 neutropenia (absolute neutrophil count <500 cells/cubic meter [cells/mm^3]) for >7 days; Grade 4 neutropenia with coincident fever; Grade 4 thrombocytopenia (platelets <25,000 cells/mm3) for >7 days; Platelet count <10,000 cells/mm3; Grade 3 thrombocytopenia with clinically significant bleeding; Delay in initiation of the subsequent therapy cycle by >7 days due to treatment-related toxicity; >=Grade 3 nonhematological toxicity except >=Grade 3 nausea/emesis occurred in the absence of optimal antiemetic therapy; >=Grade 3 diarrhea occurred in the absence of optimal supportive therapy with loperamide/comparable antidiarrheal; Grade 3 fatigue for <1 week; Other Grade 3 nonhematological toxicity that could be safely, reliably controlled to <=Grade 2 with appropriate treatment.",
        "  Time frame: Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21",
        "Results 1: ",
        "  Arm/Group Title: Phase 1: MLN8237 10 mg",
        "  Arm/Group Description: MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles for a maximum of 24 months, or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study.",
        "  Overall Number of Participants Analyzed: 1",
        "  Measure Type: Number",
        "  Unit of Measure: participants  0",
        "Results 2: ",
        "  Arm/Group Title: Phase 1: MLN8237 20 mg",
        "  Arm/Group Description: MLN8237 (alisertib) 20 mg, enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles for a maximum of 24 months, or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study.",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: participants  0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 13/23 (56.52%)",
        "  Anaemia 2/23 (8.70%)",
        "  Febrile neutropenia 3/23 (13.04%)",
        "  Neutropenia 2/23 (8.70%)",
        "  Leukopenia 1/23 (4.35%)",
        "  Thrombocytopenia 1/23 (4.35%)",
        "  Pancytopenia 0/23 (0.00%)",
        "  Atrial fibrillation 1/23 (4.35%)",
        "  Myocardial ischaemia 0/23 (0.00%)",
        "  Pericardial effusion 0/23 (0.00%)",
        "  Inappropriate antidiuretic hormone secretion 0/23 (0.00%)",
        "  Keratitis 0/23 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/1 (100.00%)",
        "  Anaemia 0/1 (0.00%)",
        "  Febrile neutropenia 0/1 (0.00%)",
        "  Neutropenia 1/1 (100.00%)",
        "  Leukopenia 1/1 (100.00%)",
        "  Thrombocytopenia 0/1 (0.00%)",
        "  Pancytopenia 0/1 (0.00%)",
        "  Atrial fibrillation 0/1 (0.00%)",
        "  Myocardial ischaemia 0/1 (0.00%)",
        "  Pericardial effusion 0/1 (0.00%)",
        "  Inappropriate antidiuretic hormone secretion 0/1 (0.00%)",
        "  Keratitis 0/1 (0.00%)"
    ]
}